Therefore, VEGFR2 expression analysis using the V-85 antibody in normal and tumor tissues (those stained with the 55B11 antibody) would be required to properly predict the safety of our TACTICs approach and potentially expand its indication to other solid tumors. Here, KDR is linked to neoplasm.